Replimune Group (REPL) Competitors

Replimune Group (NASDAQ:REPL) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, community ranking, risk, analyst recommendations, media sentiment, dividends, profitability, valuation and earnings.

Is REPL or ACAD more profitable?

ACADIA Pharmaceuticals has a net margin of 13.83% compared to Replimune Group's net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 25.83% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Replimune Group	N/A	-53.12%	-41.49%
ACADIA Pharmaceuticals	13.83%	25.83%	14.71%

Which has more risk and volatility, REPL or ACAD?

Replimune Group has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500.

Do institutionals & insiders have more ownership in REPL or ACAD?

92.5% of Replimune Group shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 8.8% of Replimune Group shares are owned by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Does the media refer more to REPL or ACAD?

In the previous week, ACADIA Pharmaceuticals had 9 more articles in the media than Replimune Group. MarketBeat recorded 12 mentions for ACADIA Pharmaceuticals and 3 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.80 beat ACADIA Pharmaceuticals' score of 0.56 indicating that Replimune Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Replimune Group	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts prefer REPL or ACAD?

Replimune Group presently has a consensus target price of $17.29, suggesting a potential upside of 70.47%. ACADIA Pharmaceuticals has a consensus target price of $25.25, suggesting a potential upside of 43.71%. Given Replimune Group's stronger consensus rating and higher probable upside, research analysts clearly believe Replimune Group is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Replimune Group	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.13
ACADIA Pharmaceuticals	0 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.59

Which has higher earnings and valuation, REPL or ACAD?

ACADIA Pharmaceuticals has higher revenue and earnings than Replimune Group. Replimune Group is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Replimune Group	N/A	N/A	-$215.79M	-$3.05	-3.32
ACADIA Pharmaceuticals	$726.44M	4.02	-$61.29M	$0.78	22.53

Does the MarketBeat Community prefer REPL or ACAD?

ACADIA Pharmaceuticals received 728 more outperform votes than Replimune Group when rated by MarketBeat users. Likewise, 73.14% of users gave ACADIA Pharmaceuticals an outperform vote while only 63.46% of users gave Replimune Group an outperform vote.

Company	Underperform	Outperform
Replimune Group	Outperform Votes 165 63.46%	Underperform Votes 95 36.54%
ACADIA Pharmaceuticals	Outperform Votes 893 73.14%	Underperform Votes 328 26.86%

Summary

ACADIA Pharmaceuticals beats Replimune Group on 13 of the 18 factors compared between the two stocks.